SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: GlobeNewswire
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it has commenced an underwritten public offering of shares of its common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock). SAB BIO also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All of the shares (and any pre-funded warrants) in the proposed offering are to be sold by SAB BIO. The Company intends to use the net proceeds it receives from this offering, together with its existing cash, cash equivalents and marketable securities, primarily to fund the continued development of our cl
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
- SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
- SAB Biotherapeutics announces public stock offering; shares down [Seeking Alpha]Seeking Alpha
SABS
Sec Filings
- 3/19/26 - Form 8-K
- 3/19/26 - Form 424B5
- 3/17/26 - Form 424B5
- SABS's page on the SEC website